These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25831765)

  • 21. Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
    Lonial S; Boise LH
    Oncology (Williston Park); 2011 Nov; 25 Suppl 2():25-31. PubMed ID: 25188480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteasome inhibitors.
    Cvek B
    Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteasome inhibitor-associated thrombotic microangiopathy: A review of cases reported to the FDA adverse event reporting system and published in the literature.
    Nguyen MN; Nayernama A; Jones SC; Kanapuru B; Gormley N; Waldron PE
    Am J Hematol; 2020 Sep; 95(9):E218-E222. PubMed ID: 32291777
    [No Abstract]   [Full Text] [Related]  

  • 24. [Myeloma therapy (3) Trends in development of new drugs].
    Ri M; Iida S
    Rinsho Ketsueki; 2013 Aug; 54(8):715-8. PubMed ID: 24005429
    [No Abstract]   [Full Text] [Related]  

  • 25. Proteasome inhibitors: introduction.
    Heuck CJ; Shaughnessy JD
    Semin Hematol; 2012 Jul; 49(3):193-5. PubMed ID: 22726541
    [No Abstract]   [Full Text] [Related]  

  • 26. The emerging role of carfilzomib combination therapy in the management of multiple myeloma.
    Moreau P
    Expert Rev Hematol; 2014 Apr; 7(2):265-90. PubMed ID: 24521249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
    Berkowitz A; Walker S
    Clin J Oncol Nurs; 2012 Feb; 16(1):86-9. PubMed ID: 22297012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
    Thompson JL
    Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib.
    Piro E; Kropp M; Cantaffa R; Lamberti AG; Carillio G; Molica S
    Ann Hematol; 2012 Nov; 91(11):1827-8. PubMed ID: 22584850
    [No Abstract]   [Full Text] [Related]  

  • 30. Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
    Pantani L; Zamagni E; Zannetti BA; Pezzi A; Tacchetti P; Brioli A; Mancuso K; Perrone G; Rocchi S; Tosi P; Cavo M
    Ann Hematol; 2014 Jan; 93(1):123-8. PubMed ID: 23864035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk stratification in multiple myeloma, part 2: the significance of genetic risk factors in the era of currently available therapies.
    Biran N; Jagannath S; Chari A
    Clin Adv Hematol Oncol; 2013; 11(9):578-83. PubMed ID: 24518521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Innovations in treatment and response evaluation in multiple myeloma.
    Wester R; Sonneveld P
    Haematologica; 2016 May; 101(5):518-20. PubMed ID: 27132277
    [No Abstract]   [Full Text] [Related]  

  • 33. Proteasome inhibitor therapy for Waldenström's macroglobulinemia.
    Dimopoulos MA; Terpos E; Kastritis E
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):235-7. PubMed ID: 23562304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
    Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential or combination therapy for multiple myeloma.
    Nooka A; Lonial S
    Expert Rev Hematol; 2012 Oct; 5(5):533-45. PubMed ID: 23146057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Complications and managements in treatment of melphalan, prednisone and new agents].
    Ishida T
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():649-52. PubMed ID: 25831841
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical translation in multiple myeloma: from bench to bedside.
    Laubach J; Hideshima T; Richardson P; Anderson K
    Semin Oncol; 2013 Oct; 40(5):549-53. PubMed ID: 24135399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging biological insights and novel treatment strategies in multiple myeloma.
    Gentile M; Recchia AG; Mazzone C; Morabito F
    Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib for the treatment of multiple myeloma.
    Grosicki S; Barchnicka A; Jurczyszyn A; Grosicka A
    Expert Rev Hematol; 2014 Apr; 7(2):173-85. PubMed ID: 24617331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.
    Herndon TM; Deisseroth A; Kaminskas E; Kane RC; Koti KM; Rothmann MD; Habtemariam B; Bullock J; Bray JD; Hawes J; Palmby TR; Jee J; Adams W; Mahayni H; Brown J; Dorantes A; Sridhara R; Farrell AT; Pazdur R
    Clin Cancer Res; 2013 Sep; 19(17):4559-63. PubMed ID: 23775332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.